Medical Appliances and Equipment Stocks Technical Report -- Boston Scientific, Abbott Laboratories, Medtronic, Stryker, and Edwards Lifesciences

News provided by

www.erionline.net

Sep 18, 2015, 08:30 ET

NEW YORK, September 18, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Boston Scientific Corporation (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Medtronic PLC (NYSE: MDT), Stryker Corporation (NYSE: SYK), and Edwards Lifesciences Corporation (NYSE: EW). Free research report on Boston Scientific can be accessed at https://www.erionline.net/reports?keyword=BSX On Thursday, September 17, 2015, the NASDAQ Composite ended at 4,893.95, up 0.10%, the Dow Jones Industrial Average edged 0.39% lower, to finish the day at 16,674.74, and the S&P 500 closed at 1,990.20, down 0.26%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.

On Thursday, shares in Boston Scientific Corp. recorded a trading volume of 8.41 million shares, close to their three months average volume of 8.40 million shares. The stock ended the day 0.53% higher at $17.20. Boston Scientific Corp.'s stock has fallen by 2.05% in the last one month and 4.55% in the previous three months. However, the stock has surged 29.81% on YTD basis. The company is trading above its 50-day and 200-day moving averages by 0.25% and 4.09%, respectively. Furthermore, shares of Boston Scientific Corp. have a Relative Strength Index (RSI) of 54.01. Sign up and read the free notes on BSX at:

https://www.erionline.net/reports?keyword=BSX

Abbott Laboratories' stock edged 0.87% higher, to close Thursday's session at $44.24. The stock recorded a trading volume of 7.19 million shares, above its three months average volume of 5.99 million shares. Over the last one month and the previous three months, Abbott Laboratories' shares have lost 12.29% and 10.99%, respectively. Additionally, the stock has edged 0.23% lower since the start of this year. The company is trading 7.85% and 5.44% below its 50-day and 200-day moving averages, respectively. Furthermore, Abbott Laboratories' stock traded at a PE ratio of 28.00 and has an RSI of 42.63. The complimentary notes on ABT can be downloaded in PDF format at:

https://www.erionline.net/reports?keyword=ABT

Medtronic PLC's stock finished Thursday's session 0.98% higher at $70.81. A total of 5.97 million shares were traded, which was above its three months average volume of 5.71 million shares. Over the last one month and the previous three months, Medtronic PLC's shares have lost 9.32% and 7.24%, respectively. Additionally, the stock has declined 1.04% since the beginning of 2015. The company's shares are trading below their 50-day and 200-day moving averages by 5.21% and 5.62%, respectively. Medtronic PLC's stock traded at a PE ratio of 29.63 and has an RSI of 44.96. Register for free on Equity Research Institute and access the latest research on MDT at:

https://www.erionline.net/reports?keyword=MDT

On Thursday, shares in Stryker Corp. ended the session 0.04% lower at $100.56. The stock reported a trading volume of 1.67 million shares, above its three months average volume of 1.30 million shares. Shares of the company traded at a PE ratio of 41.21. Although, Stryker Corp.'s shares have declined 3.60% in the last one month, it has advanced 3.88% in the previous three months and 7.39% on YTD basis. The company is trading 0.89% above its 50-day moving average and 5.82% above its 200-day moving average. Moreover, shares of Stryker Corp. have an RSI of 54.24. The complete research on SYK is available for free at:

https://www.erionline.net/reports?keyword=SYK

Edwards Lifesciences Corp.'s stock edged 0.73% higher, to close the day at $141.61. The stock recorded a trading volume of 0.65 million shares, below its three months average volume of 1.09 million shares. Over the last one month and over the past three months, Edwards Lifesciences Corp.'s shares have fallen by 2.52% and 2.41%, respectively. However, the stock has advanced 11.17% since the start of this year. The company's shares are trading 3.09% above their 200-day moving average. Additionally, Edwards Lifesciences Corp. traded at a PE ratio of 35.31 and has an RSI of 49.06. Free in-depth research on EW is available at:

https://www.erionline.net/reports?keyword=EW

About Equity Research Institute:

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY

ERI, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.erionline.net.

RESTRICTIONS

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) erionline.net.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.erionline.net